Patient-targeted molecular therapies
Section edited by Francesco Chiappelli and Francesco Piva
The mission of this section is to enrich the overall mandate of the journal through effectively capturing the growing sector of molecular targeted therapies with broad therapeutic applicability, benefiting from a patient-centered outcomes research focus and translational effectiveness approach, to generate adequate information during research and early development stages, as well as consensus on the best available evidence.
This section has a unique and defining objective and rationale relative to the other sections that focus primarily on translational immunology and oncology. In contrast, this section will add the complementary discourse between translational research and translational effectiveness. In doing so, it will expand the overall vision of the journal, and address current, timely and cutting edge research and reviews about patient-centered targeted therapies, in context of translating cost and benefit effectiveness to specific clinical settings.
Ebola: translational science considerations
Francesco Chiappelli, et al
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts
Woan-Ruoh Lee, et al
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
Yael Babichev, et al
Annual Journal Metrics
56 days to first decision for reviewed manuscripts only
51 days to first decision for all manuscripts
104 days from submission to acceptance
10 days from acceptance to publication
2,714 Altmetric mentions